Potential early biomarkers of sarcopenia among independent older adults

Montes, Ana Coto; Boga, José Antonio; Millo, Carlos Bermejo; Rubio-González, Adrian; Potes, Yaiza; Vega‐Naredo, Ignacio; Reig, Marta Martínez; Rizos, Luis Romero; Jurado, Pedro; Pérez-Solano, Juan J.; Caballero, Beatriz

doi:10.1016/j.maturitas.2017.08.009

Cited by 41 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 85 Moreover, a recent interesting French study analyzed the relationships between the accumulation of AGEs, assessed by skin autofluorescence (AF), and frailty in 423 older community-dwellers aged ≥75 years, showing that the accumulation of AGEs was not associated with prevalent or incident frailty but with the 4-year risk of exhaustion and low energy expenditure. 87 Nevertheless, increased levels of AGEs are associated with sarcopenia in elderly subjects, 86 while decreased levels of RAGEs are markers of severity and accelerated aging in COPD patients; 43 oxLDL levels, as described in the section “Oxidative stress and CVDs”, correlate with arterial stiffness and athero-genesis in the elderly, not predicting mortality; 26 , 27 -HNE levels are elevated in elderly subjects with NDs (ie, AD, PD, HD, and ALS) 88 and sarcopenia; 89 F 2 -isoprostanes urinary levels are increased in several diseases frequently diagnosed in elderly patients, such as depression, 90 age-related macular degeneration (AMD), 91 AD and HD, 92 COPD, 41 and CKD, where it correlates with disease progression; 79 MDA increased plasma levels correlate with low cognitive performance in institutionalized elderly subjects; 54 its levels increase in elderly subjects with T2D but not with IGT 38 and in CKD, where its levels are inversely related to glomerular filtration rate (GFR) and positively correlated with uremic toxins and severity of glomerulosclerosis; 79 NT levels are used as biomarkers of COPD 41 and sarcopenia 93 in elderly subjects, and high levels are associated with vascular endothelial dysfunction with aging; 30 , 31 DNA modifications, 8oxodG and 7,8-dihydro-8-oxoguanosine (8oxoGuo), are excreted into the urine and measured with enzyme-linked immunosorbent assay. Both are markers of inflammation and carcinogenesis in the elderly.…”

Section: Biomarkers Of Oxidative Stressmentioning

confidence: 99%

Oxidative stress, aging, and diseases

Liguori

Russo

Curcio

et al. 2018

CIA

2,954

1,843

View full text Add to dashboard Cite

Reactive oxygen and nitrogen species (RONS) are produced by several endogenous and exogenous processes, and their negative effects are neutralized by antioxidant defenses. Oxidative stress occurs from the imbalance between RONS production and these antioxidant defenses. Aging is a process characterized by the progressive loss of tissue and organ function. The oxidative stress theory of aging is based on the hypothesis that age-associated functional losses are due to the accumulation of RONS-induced damages. At the same time, oxidative stress is involved in several age-related conditions (ie, cardiovascular diseases [CVDs], chronic obstructive pulmonary disease, chronic kidney disease, neurodegenerative diseases, and cancer), including sarcopenia and frailty. Different types of oxidative stress biomarkers have been identified and may provide important information about the efficacy of the treatment, guiding the selection of the most effective drugs/dose regimens for patients and, if particularly relevant from a pathophysiological point of view, acting on a specific therapeutic target. Given the important role of oxidative stress in the pathogenesis of many clinical conditions and aging, antioxidant therapy could positively affect the natural history of several diseases, but further investigation is needed to evaluate the real efficacy of these therapeutic interventions. The purpose of this paper is to provide a review of literature on this complex topic of ever increasing interest.

show abstract

Section: Biomarkers Of Oxidative Stressmentioning

confidence: 99%

Oxidative stress, aging, and diseases

Liguori

Russo

Curcio

et al. 2018

CIA

2,954

1,843

View full text Add to dashboard Cite

show abstract

“…1), we finally included 14 studies assessing the difference in health care costs between individuals with or without sarcopenia [10][11][12][13][14][15][16][17][18][19][20][21][22][23]. Sixteen studies were rejected because of duplicate (n = 2) [11,20], wrong outcomes (n = 13) [24][25][26][27][28][29][30][31][32][33][34][35][36] or wrong exposure factor (n = 1) [38].…”

Section: Literature Searchmentioning

confidence: 99%

The health economics burden of sarcopenia: a systematic review

et al. 2019

View full text Add to dashboard Cite

Despite of better knowledge about sarcopenia, an optimal understanding of its consequences from a public health perspective remains a challenge. Specifically, the economic burden of the illness is unclear. As a support for the public health policy makers and other health actors, our objective was to perform a systematic review of the literature comparing healthcare costs between sarcopenic and non-sarcopenic patients (under the registration number CRD42018099291). A search for relevant articles was conducted on the Medline and Scopus databases. Rigorous eligibility criteria were established (e.g., subjects with sarcopenia, both men and women, mean age of the sarcopenic population) and applied by two investigators to identify suitable studies. The first screening phase, performed by 2 independent reviewers, covered 455 references. Fourteen relevant studies were included in the final analysis. Overall, we noted an important heterogeneity between studies in the way of assessing sarcopenia (i.e. operational definitions, tools and cut-offs used). There were also large variations between studies in their cost analysis settings (i.e., discrepancies in time horizon, types and sources of economic data). Most of the studies focused on hospitalization costs following surgery for a specific disease such as cancer. Finally, 11 out of the 14 studies reported higher healthcare costs for sarcopenic patients. However, most of the included studies have important methodological bias (e.g. potential confusion factors rarely taken into account), and low to moderate quality scores. More standardized research, taking into account all the limitations of the published studies, should be conducted to assess the true impact of sarcopenia on healthcare consumption.

show abstract

“…Four articles [8,16,24,29] were divided into two or four studies as the participants were categorized into several groups according their characteristics. Eight studies [7][8][9]19,[28][29][30] addressed the association between sarcopenia and hypertension, and 11 studies [18,[25][26][27]31] focused on the association between handgrip strength and hypertension. The sarcopenia was defined by three methods, the European Working Group on Sarcopenia in Older People (EWGSOP) criteria [32], the Asian Working Group for Sarcopenia (AWGS) criteria, and ASM/weight (kg) less than one standard deviation (SD).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Six studies were conducted in China [18,19,28,31], two each in Republic of Korea [8] and Japan [26], and United States [9,25,34,35], one each in Turkey [30], Switzerland [27], Italy [7], and Spain [29].…”

Section: Study Characteristicsmentioning

confidence: 99%

Sarcopenia is associated with hypertension in older adults: a systematic review and meta-analysis

Bai

Fang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Sarcopenia and handgrip strength have been observed and correlated in association with hypertension among the old-age people. However, the results reported in different studies were inconsistent. In the current study, we conducted a systematic review and meta-analysis to reveal the significant association between sarcopenia, handgrip strength, and hypertension in older adults. Methods: PubMed, MEDLINE, Cochrane Library, and EMBASE databases were searched from inception to 15 November, 2019 to retrieve the original research studies that addressed the association between sarcopenia, handgrip strength, and hypertension. All the relevant data were retrieved, analyzed, and summarized. Results: 19 studies met the inclusion criteria and a total of 21301 participants were included in the meta-analysis. Eight eligible studies have reported the odd ratios (ORs) of hypertension and the ORs ranged from 0.41 to 4.38. When pooled the ORs together, the summarized ORs was 1.29 [95% confidence interval (CI) =1.00-1.67]. The summarized ORs for the Asian group 1.50 (95% CI=1.35-1.67) was significantly higher than that of Caucasian group 1.08 (95% CI=0.39-2.97). Eleven studies have provided the data on association between handgrip strength and hypertension. The overall ORs and 95% CI was 0.99 (95% CI=0.80-1.23), showing no significant association. Conclusion: Sarcopenia was associated with hypertension, but no correlation was found between handgrip strength and hypertension in older adults.

show abstract

Potential early biomarkers of sarcopenia among independent older adults

Cited by 41 publications

References 29 publications

Oxidative stress, aging, and diseases

Oxidative stress, aging, and diseases

The health economics burden of sarcopenia: a systematic review

Sarcopenia is associated with hypertension in older adults: a systematic review and meta-analysis

Contact Info

Product

Resources

About